August 28, 2023
Reporter, Health Care Inc. Writer
Hello, you scalliwags. It’s finally happening: This week, Medicare will name the first 10 drugs that will be subject to price negotiations. What drugs will be on there? Eliquis? Enbrel? Entresto? Make sure you follow stat news dot com and especially our D.C. reporters who are closely tracking this. And as always, drop me a line on anything that piques your interest, drug prices or otherwise: bob.herman@statnews.com.

medicare advantage

Feds levy more fines on MA plans
Adobe CMS

Adobe

CMS fined three different Medicare Advantage plans this month, each one getting dinged differently for the way they overcharged their members. But there was one common theme: The MA plans’ technology systems screwed up. (Similar to the EmblemHealth fine we highlighted a couple months ago. Spoiler alert: EmblemHealth makes another appearance here.)

These types of federal audits are routine. And the penalties are minuscule for the insurance companies — roughly equivalent to some pennies under a couch cushion. But they could serve as warnings for companies to clean up their compliance and IT infrastructure before regulators knock on their doors again.

Read the story to find out which companies got fined and what kind of message the penalties are sending.


private equity

Some transparency is coming for PE firms

Private equity is transforming the health care industry — for the worse, mostly — with its buy-ups of physician practices and nursing homes. Soon, these mysterious funds will have to open their books for annual audits and give investors quarterly statements on their fund performance, fees, and expenses under new rules from the Securities and Exchange Commission, my colleague Tara Bannow reports.

This marks a significant change for an industry that’s become accustomed to operating under the radar. Despite that, the final rules didn’t pack as much of a punch as the original version released in early 2022.

Perhaps the biggest difference: While the draft would have outright prohibited the funds from doing things “contrary to the public interest,” the final version says they can go right ahead, so long as they let their investors know. Examples of such activities include taking money out of the fund to pay for their own expenses and borrowing money from fund clients. The draft would also have required private equity funds to seek third-party fairness opinions to ensure their prices are fair prior to closing deals. The final rule instead adds the option of getting a third-party assessment of the deal’s value, without a fairness determination.

Still, the changes go a long way toward protecting investors, which include public worker pension funds and university endowments. SEC Chair Gary Gensler said the rules are for all investors, “big or small, institutional or retail, sophisticated or not.”


stock market

The next big health care IPO?

Health care IPOs have been dormant for several years, outside of some biotech, digital health, and medical device companies. But that could change if revenue cycle giant Waystar goes public soon.

Reuters reported Waystar has hired banks to explore an initial public offering for either later this year or early next. Waystar would be valued at $8 billion. That would make it bigger than one of its main competitors, R1 RCM, which currently has a market cap around $7 billion and has extremely close ties to the Catholic hospital system Ascension

Waystar also would have a higher valuation than Ensemble Health Partners, the revenue cycle firm spawned out of Catholic hospital system Bon Secours Mercy Health. Private equity firms Berkshire Partners and Warburg Pincus acquired significant stakes in Ensemble last year, valuing the company at $5 billion. (Bon Secours still owns a minority stake in Ensemble, enough to shovel $30 million of income into Bon Secours’ coffers so far this year.)

Waystar works with thousands of hospitals, physician practices, surgery centers, and other providers on ways to maximize their revenue — i.e., collecting payments from patients, pursuing more “accurate” coding, installing medical claims technology, appealing denials from insurance companies. Bain Capital, a minority investor, recently said Waystar had more than $600 million in revenue in 2022. If you know other important nuggets about Waystar, or any other private health care companies that are considering an IPO or SPAC, let me know.



the obesity revolution

The dearth of obesity physicians

By 2030, experts predict half of U.S. adults will have obesity. And yet, fewer than 100 doctors have completed a fellowship in obesity medicine and are actively practicing, my colleague Simar Bajaj reports.

That’s not to say every person with obesity needs to see a specialist. Many don’t. But a lot of that effort and care falls on primary care physicians, many of whom are already strained and may not have time to think more holistically about the best ways to treat obesity.

Read Simar’s story to understand why obesity medicine specialists think there should be more among their ranks, and how Novo Nordisk (the maker of anti-obesity drugs Ozempic and Wegovy) muddies the waters by funding medical school curricula and fellowship programs.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Industry odds and ends

  • The Federal Trade Commission has been aggressive in stopping horizontal hospital mergers under Lina Khan. It’s unclear what, if anything, will change with that perspective now that Khan officially named Henry Liu, a Covington & Burling attorney, as the director of the FTC’s Bureau of Competition.
  • Children’s Healthcare of Atlanta just registered a 17% operating margin in the second quarter of this year. Seventeen percent. And the hospital is on pace for $2.5 billion of revenue this year. Wild.
  • You know what is the fastest-growing part of SSM Health, the massive hospital system in the Midwest? Its pharmacy benefit manager. Combined revenues for Navitus (the main PBM) and Lumicera (SSM’s specialty pharmacy) are up more than 20% this year.
  • Analytics firm Trilliant Health is open-sourcing its national provider directory, for free. This comes a little less than a year after the government asked about the feasibility of this very thing.
  • The University of Alabama Birmingham is threatening to kick out the company that runs the proton beam therapy center at its campus because the company is not making lease and staffing payments. This has been foreshadowed for a while.
  • Oregon is not happy with the PBMs that manage drug prescriptions for its Medicaid program. Not happy at all.
  • An FDA advisory panel looked at two surgical systems that are used in a controversial blood pressure treatment. One device got its blessing, and the other didn’t, my colleague Lizzy Lawrence reports.
  • “The U.S. has at least 600 fewer nursing homes than it did six years ago,” the Wall Street Journal reports in a new data analysis.

The Meme Ward

Health Care Inc. Meme - Issue 57


Thanks for reading! More next week.


Enjoying Health Care Inc.? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.